MSFP
RVNC

Mark Sheptoff Financial Planning’s Revance Therapeutics, Inc. RVNC Stock Holding History

Mark Sheptoff Financial Planning’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,000
Closed -$54K – 405
2022
Q3 		$54K Buy
+2,000
New +$40.6K 0.03% 139

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Mark Sheptoff Financial Planning's RVNC Position: Q4 2022 in Review

Mark Sheptoff Financial Planning sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2022, closing a stake of 2,000 shares — an estimated $54K sold.

Mark Sheptoff Financial Planning first reported a position in RVNC in Q3 2022 and held it in 1 quarter. The position peaked at $54K in Q3 2022. 193 funds tracked by Wall St. Rank hold RVNC as of Q4 2022.

  • Mark Sheptoff Financial Planning reported no remaining Revance Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • Mark Sheptoff Financial Planning sold 2,000 Revance Therapeutics, Inc. shares in Q4 2022, an estimated $54K.
  • Mark Sheptoff Financial Planning first reported a position in Revance Therapeutics, Inc. in Q3 2022 and held it in 1 quarter.
  • Mark Sheptoff Financial Planning's Revance Therapeutics, Inc. position peaked at $54K in Q3 2022.
  • 193 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2022.

Based on Mark Sheptoff Financial Planning's 13F filing for Q4 2022, filed 14 Feb 2023.